Positive phase IIb data with MIN-101 in schizophrenia paves the way to pivotal testing and gives patients hope for their negative symptoms, Minerva Neurosciences Inc. spokesman William Boni told BioWorld Today. “I don’t want to use any words like ‘breakthrough,’” he said, because there needs to be more testing done, “but there is no effective treatment for negative symptoms at this point.”